Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot study

F] fluoro-D-glucose accumulation, tumor cell proliferation markers, prealbumin levels, tumor PD-L1, and stromal CD4 expression. When exploratory partial metabolic response (PMR) criteria of a ≥ 20% or ≥ 10% decrease in FMISO SUV were applied, progression-free survival differed significantly between PMR and non-PMR groups, whereas overall survival did not differ significantly. FMISO PET may serve as an exploratory tool for assessing early treatment response to ICIs in patients with advanced NSCLC. However, further studies are required to validate these findings.